HSP90AA1 and hepatocellular carcinoma: In our pilot study, we found that the expression of NAT10 was associated with risk and prognosis of HCC using data from the TCGA database, and acRIP-Seq assay also indicated that the HSP90AA1 was the potential target of the ac4C modification of NAT10 in HCC.